MicroTech Medical (Hangzhou) (2235) Stock Overview
Provides diabetes management, diabetes treatment, and diabetes monitoring medical devices in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2235 from our risk checks.
2235 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
MicroTech Medical (Hangzhou) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.09 |
| 52 Week High | HK$9.17 |
| 52 Week Low | HK$4.00 |
| Beta | 0.45 |
| 1 Month Change | 3.20% |
| 3 Month Change | -16.98% |
| 1 Year Change | 50.85% |
| 3 Year Change | -17.75% |
| 5 Year Change | n/a |
| Change since IPO | -76.75% |
Recent News & Updates
Here's Why MicroTech Medical (Hangzhou) (HKG:2235) Can Manage Its Debt Despite Losing Money
Oct 15
MicroTech Medical (Hangzhou) Co., Ltd.'s (HKG:2235) Price In Tune With Revenues
Jul 30Recent updates
Here's Why MicroTech Medical (Hangzhou) (HKG:2235) Can Manage Its Debt Despite Losing Money
Oct 15MicroTech Medical (Hangzhou) Co., Ltd.'s (HKG:2235) Price In Tune With Revenues
Jul 30MicroTech Medical (Hangzhou) (HKG:2235) Is In A Good Position To Deliver On Growth Plans
Jun 23We Think The Compensation For MicroTech Medical (Hangzhou) Co., Ltd.'s (HKG:2235) CEO Looks About Right
May 21MicroTech Medical (Hangzhou) Co., Ltd. (HKG:2235) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable
Apr 08MicroTech Medical (Hangzhou) (HKG:2235) Is In A Good Position To Deliver On Growth Plans
Sep 22News Flash: One MicroTech Medical (Hangzhou) Co., Ltd. (HKG:2235) Analyst Has Been Trimming Their Revenue Forecasts
Jan 20MicroTech Medical (Hangzhou) (HKG:2235) Is In A Good Position To Deliver On Growth Plans
Jan 18Shareholder Returns
| 2235 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 5.0% | -3.9% | -2.9% |
| 1Y | 50.9% | 51.0% | 27.0% |
Return vs Industry: 2235 matched the Hong Kong Medical Equipment industry which returned 51% over the past year.
Return vs Market: 2235 exceeded the Hong Kong Market which returned 27% over the past year.
Price Volatility
| 2235 volatility | |
|---|---|
| 2235 Average Weekly Movement | 6.0% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.5% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 2235 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2235's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 645 | Pan Zheng | www.microtechmd.com |
MicroTech Medical (Hangzhou) Co., Ltd. provides diabetes management, diabetes treatment, and diabetes monitoring medical devices in China and internationally. The company offers Equil patch insulin pump systems; AiDEX and LinX continuous glucose monitoring systems; POCT analyzer systems; closed-loop artificial pancreas systems; blood glucose monitoring systems; Exactive Pro blood glucose, blood ketone, and uric acid monitoring system; API open platform; and diabetes digital management software. It also involved in scientific research and technical services; business services; wholesale and retail; manufacturing; and commercials business.
MicroTech Medical (Hangzhou) Co., Ltd. Fundamentals Summary
| 2235 fundamental statistics | |
|---|---|
| Market cap | HK$2.98b |
| Earnings (TTM) | -HK$30.50m |
| Revenue (TTM) | HK$485.76m |
Is 2235 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2235 income statement (TTM) | |
|---|---|
| Revenue | CN¥440.73m |
| Cost of Revenue | CN¥215.18m |
| Gross Profit | CN¥225.56m |
| Other Expenses | CN¥253.23m |
| Earnings | -CN¥27.68m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.066 |
| Gross Margin | 51.18% |
| Net Profit Margin | -6.28% |
| Debt/Equity Ratio | 1.5% |
How did 2235 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 10:04 |
| End of Day Share Price | 2025/12/10 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MicroTech Medical (Hangzhou) Co., Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Mujun Shen | Citic Securities Co., Ltd. |
| Yinglong Pan | Goldman Sachs |